Abstract
Purpose To develop SCOPE (Small-lesion COntextual Pancreatic Evaluator), a deep learning model designed to improve CT detection of small pancreatic lesions—pancreatic ductal adenocarcinoma (PDAC), pancreatic neuroendocrine tumors (PanNETs), and cystic lesions—by integrating voxel-level features with global context.
Materials and Methods This retrospective study used three independent datasets. A development cohort of 4,065 contrast-enhanced CT scans was used to train a deep neural network that performs pancreas, ductal, and lesion segmentation with an integrated classification head. A metamodel combined segmentation-derived and global contextual signals for case-level prediction. Performance was assessed on (1) an internal holdout test set (n = 605), (2) an external multi-institutional PDAC dataset from the PANORAMA challenge (n = 2,238), and (3) an expert-curated small-lesion reader study (n = 200). Areas under the receiver operating characteristic curve (AUCs) were compared using DeLong test; sensitivities and specificities using McNemar’s test.
Results On the internal test set, SCOPE improved lesion-versus-normal AUC compared with the best segmentation baseline (0.974 [95% CI: 0.964, 0.984] vs 0.956; P = .006) and increased small-lesion sensitivity at 95% specificity (0.727 [95% CI: 0.653, 0.801] vs 0.600; P = .012). Performance gains were observed across lesion classes, with significant improvements for PDAC and PanNET detection. On the external dataset, SCOPE improved PDAC-versus-non-PDAC AUC (0.978 vs 0.861, P < .001) and achieved higher sensitivity at 90% and 95% specificity without retraining. For the small-lesion reader study, SCOPE achieved lesion-versus-normal AUC of 0.922 and performed within the range of subspecialty abdominal radiologists; SCOPE provided the correct diagnosis in 14.5% (29/200) of cases in which two or more readers were incorrect.
Conclusion SCOPE improves early detection of small, potentially curable, pancreatic lesions on CT by combining local segmentation and global pancreatic context. Its consistent performance across internal, external, and reader datasets supports potential use as a concurrent reader for earlier and more accurate pancreatic lesion detection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research grant support from the Lustgarten Foundation: FLR., FLR, AB, EAS, FT, LCC, EKF and Microsoft AI for Good.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Johns Hopkins Hospital gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
